GMAB ▲ +3.5% - Genmab A/S $GMAB Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma 26-OCT-2026 07:03 AM ET